Christi Shaw, Kite CEO

ASH: Gilead­'s Kite un­veils more da­ta on Yescar­ta's win in sec­ond-line lym­phoma pa­tients, set­ting up bat­tle for SOC

As a spate of re­searchers work dili­gent­ly on next-gen CAR-T cell ther­a­pies, the big play­ers in the cur­rent gen­er­a­tion of those drugs are still an­gling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.